Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Tuberculosis (Edinburgh, Scotland)
|
May 22, 2003
Progress in TB drug development and what is still needed
Ken Duncan
Current Opinion in Microbiology
|
September 29, 2004
Prospects for new antitubercular drugs
Ken Duncan, Clifton E Barry
Current Molecular Medicine
|
May 17, 2007
Current strategies for identifying and validating targets for new treatment-shortening drugs for TB
Kerstin J Williams, Ken Duncan
Tuberculosis (Edinburgh, Scotland)
|
April 27, 2005
HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis
Tanya Parish, Merrill Schaeffer, Gretta Roberts, et al.
The Lancet. Global Health
|
November 14, 2024
Access to antibiotics for pneumonia and sepsis in LMICs
Amy Sarah Ginsburg, Ken Duncan, Keith P Klugman, et al.
Antimicrobial Agents and Chemotherapy
|
May 27, 2005
New small-molecule synthetic antimycobacterials
Lluis Ballell, Robert A Field, Ken Duncan, et al.
The Journal of Clinical Investigation
|
April 3, 2008
Confronting the scientific obstacles to global control of tuberculosis
Douglas B Young, Mark D Perkins, Ken Duncan, et al.
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques
|
January 2, 2007
Systems biology and its impact on anti-infective drug development
Michael P Stumpf, Brian D Robertson, Ken Duncan, et al.
Journal of Bacteriology
|
March 6, 2007
Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG
Tanya Parish, Gretta Roberts, Francoise Laval, et al.
Drug Discovery Today
|
May 2, 2026
Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator
Kelsey L Briggs, Betsy J Russell, Peter Warner, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Tuberculosis (Edinburgh, Scotland)
|
May 22, 2003
Progress in TB drug development and what is still needed
Ken Duncan
Current Opinion in Microbiology
|
September 29, 2004
Prospects for new antitubercular drugs
Ken Duncan, Clifton E Barry
Current Molecular Medicine
|
May 17, 2007
Current strategies for identifying and validating targets for new treatment-shortening drugs for TB
Kerstin J Williams, Ken Duncan
Tuberculosis (Edinburgh, Scotland)
|
April 27, 2005
HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis
Tanya Parish, Merrill Schaeffer, Gretta Roberts, et al.
The Lancet. Global Health
|
November 14, 2024
Access to antibiotics for pneumonia and sepsis in LMICs
Amy Sarah Ginsburg, Ken Duncan, Keith P Klugman, et al.
Antimicrobial Agents and Chemotherapy
|
May 27, 2005
New small-molecule synthetic antimycobacterials
Lluis Ballell, Robert A Field, Ken Duncan, et al.
The Journal of Clinical Investigation
|
April 3, 2008
Confronting the scientific obstacles to global control of tuberculosis
Douglas B Young, Mark D Perkins, Ken Duncan, et al.
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques
|
January 2, 2007
Systems biology and its impact on anti-infective drug development
Michael P Stumpf, Brian D Robertson, Ken Duncan, et al.
Journal of Bacteriology
|
March 6, 2007
Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG
Tanya Parish, Gretta Roberts, Francoise Laval, et al.
Drug Discovery Today
|
May 2, 2026
Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator
Kelsey L Briggs, Betsy J Russell, Peter Warner, et al.
Page
of 3